Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2015, XXXIX/233: 263-270 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2015, XXXIX/233: 263-270

Title: Benign prostatic hyperplasia – progress in pathophysiology and management

Authors: Dobrek Ł, Thor PJ. 

More details

01/233

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN ENGLISH.

Benign prostatic hyperplasia – progress in pathophysiology and management


Dobrek Ł, Thor PJ.

Department of Pathophysiology, Jagiellonian University Collegium Medicum in Cracow, Poland

Benign prostatic hyperplasia (BPH) is a common disease of the aging male population, in affected individuals often accompanied by metabolic syndrome. BPH is manifested by a complex range of symptoms originating from the lower urinary tract (LUTS – lower urinary tract symptoms), including disturbances resulting from impaired bladder compliance and bladder overactivity (e.g. frequency, nocturia, urinary incontinence, dysuria) and symptoms associated with the bladder outlet obstruction (e.g. the difficulty in voiding initiating, intermittency, involuntary interruption of voiding, weak urinary stream, straining to void). Despite numerous studies, the pathogenesis of BPH remains not completely understood, and the condition awaits a comprehensive description. The current pathophysiological view emphasizes the role of hormonal dysregulation, locally released in the prostate growth factors action and a complex inflammatory, BPH-associated process with the release of a number of pro-proliferative mediators. The current BPH pharmacotherapy involves administration of -1-blockers, 5--reductase inhibitors, antimuscarinic drugs (cholinolytics) and phosphodiesterase- 5-inhibitors. Progress in the BPH pathophysiology allows the disclosure of additional, potential targets of pharmacological intervention, such as -3 adrenoreceptor or CB1cannabinoid receptor agonists, P2X1 purinergic or ETA endothelin receptors antagonists, RhoA/Rho kinase system inhibitors, nitric oxide donors, drugs indirectly (luteinizing hormone – releasing hormone antagonists) or directly (antiandrogens) abolishing the effect of testosterone and its derivatives or agents blocking the action of proinflammatory cytokines. The article briefly discusses the pathophysiology of the aforementioned issues and the current BPH management along with the future, potential opportunities for pharmacotherapy of the disease, based on presented pathophysiological premises.

Key words: benign prostatic hyperplasia (BPH), BPH pathophysiology, BPH management

Pol Med J, 2015; XXXIX (233); 263–270